Contineum Therapeutics, Inc.

$13.38Close · Oct 9, 2026

News

Identification and Evaluation of [18F] PIPE-497, the First CNS-Penetrant PET Tracer for the Imaging of Lysophosphatidic Acid Receptor 1 in the Clinic
Aug 9, 2026Contineum Therapeutics
Austin Chen, Christine Sandiego, Guilia Boscutti, Lisa Wells, Chris Baccei, Thomas Schrader, Jeff Roppe, Lino Valdez, Alex Broadhead, Kymmy Lorrain, Didier Bagnol, Karin Stebbins, Mike Poon, Dan Lorrain Presented at the 2026 Gordon Research Conference on Medicinal Chemistry The post Identification and Evaluation of [18F] PIPE-497, the First CNS-Penetrant PET Tracer for the Imaging of Lysophosphatidic Acid Receptor 1 in the Clinic first appeared on Contineum Therapeutics.
PIPE-791 and BMS-986278: Two Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists with Distinct Lung Occupancy Profiles and Vascular Effects
May 18, 2026Contineum Therapeutics
Daniel S. Lorrain, Michael M. Poon, Kym I. Lorrain, Alexander R. Broadhead, Didier Bagnol, Jeffrey R. Roppe, Thomas O. Schrader, Austin C. Chen Presented at ATS 2026 The post PIPE-791 and BMS-986278: Two Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists with Distinct Lung Occupancy Profiles and Vascular Effects first appeared on Contineum Therapeutics.
LPA1 Antagonism by PIPE-791 Reduces Alveolar Epithelial Cell Apoptosis In Vitro
May 18, 2026Contineum Therapeutics
Michael M. Poon, Alexander R. Broadhead, Christopher S. Baccei, Didier Bagnol, Jeffrey R. Roppe, Thomas O. Schrader, Lino Valdez, Yifeng Xiong, Austin C. Chen, Timothy R. Watkins, Daniel S. Lorrain Presented at ATS 2026 The post LPA1 Antagonism by PIPE-791 Reduces Alveolar Epithelial Cell Apoptosis In Vitro first appeared on Contineum Therapeutics.
LPA1 receptor binding sites are abundant in multiple sclerosis patient rim lesions associated with TSPO activation and disease progression
Nov 21, 2025Contineum Therapeutics
D. Bagnol, A. R. Broadhead, C. S. Baccei, K. I. Lorrain, G. C. Edu, K. Stebbins, M. M. Poon, J. R. Roppe, T. O. Schrader, L. J. Valdez, A. C. Chen, D. S. Lorrain Presented at SFN 2025 The post LPA1 receptor binding sites are abundant in multiple sclerosis patient rim lesions associated with TSPO activation and disease progression first appeared on Contineum Therapeutics.
CNS-Penetrant LPA₁ Antagonist PIPE-791 Provides Superior Analgesia Compared to Peripherally-Restricted CTX-343 in a Rat Model of LPA-Induced Osteoarthritis
Nov 21, 2025Contineum Therapeutics
A. R. Broadhead, C. S. Baccei, D. Bagnol, K. I. Lorrain, G. C. Edu, M. M. Poon, J. R. Roppe, T. O. Schrader, L. J. Valdez, Y. Xiong, A. C. Chen, D. S. Lorrain Presented at SFN 2025 The post CNS-Penetrant LPA₁ Antagonist PIPE-791 Provides Superior Analgesia Compared to Peripherally-Restricted CTX-343 in a Rat Model of LPA-Induced Osteoarthritis first appeared on Contineum Therapeutics.
The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis
Aug 31, 2025Contineum Therapeutics
Michael Poon, Kym Lorrain, Alexander Broadhead, Karin Stebbins, Didier Bagnol, Geraldine Edu, Gregory Joseph, Christopher Baccei, Jeffrey Roppe, Thomas Schrader, Lino Valdez, Yifeng Xiong, Austin Chen, and Daniel Lorrain Respiratory Research The post The LPAR1 antagonist, PIPE-791 produces antifibrotic effects in models of lung fibrosis first appeared on Contineum Therapeutics.
Lysophosphatidic Acid Receptor Subtype-1 Antagonist PIPE-791 Reduces Neuropathic Pain in Macaques
Aug 12, 2024Contineum Therapeutics
Aldric Hama, Karin Stebbins, Chris Baccei, Daniel Lorrain, Austin Chen, Takahiro Natsume, Hiroryuki Takamatsu Presented at IASP 2024 World Congress on Pain The post Lysophosphatidic Acid Receptor Subtype-1 Antagonist PIPE-791 Reduces Neuropathic Pain in Macaques first appeared on Contineum Therapeutics.
Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis
Jul 31, 2024Contineum Therapeutics
Michael M. Poon, Kym I. Lorrain, Karin J. Stebbins, Geraldine C. Edu, Alexander R. Broadhead, Ariana J. Lorenzana, Jeffrey R. Roppe, Jill M. Baccei, Christopher S. Baccei, Austin C. Chen, Ari J. Green, Daniel S. Lorrain, and Jonah R. Chan PNAS The post Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis first appeared on Contineum Therapeutics.
Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis
May 9, 2024Contineum Therapeutics
Michael M. Poon, Kym I. Lorrain, Karin J. Stebbins, Geraldine C. Edu, Alexander R. Broadhead, Ariana O. Lorenzana, Bryanna E. Paulson, Christopher S. Baccei, Jeffrey R. Roppe, Thomas O. Schrader, Lino J. Valdez, Yifeng Xiong, Austin C. Chen &amp; Daniel S. Lorrain Scientific Reports The post Discovery of a brain penetrant small molecule antagonist targeting LPA1 receptors to reduce neuroinflammation and promote remyelination in multiple sclerosis first appeared on Contineum Therapeutics.
The muscarinic M1 antagonist PIPE-359 demonstrates remyelination in vivo through visual evoked potential (VEP) and electron microscopy (EM) of mice with experimental autoimmune encephalitis (EAE)
Aug 19, 2019Contineum Therapeutics
Geraldine C Edu, Karin J Stebbins, Alexander R Broadhead, Michael M Poon, Ariana O Lorenzana, Thomas Schrader, Yifeng Xiong, Jill Baccei, Ari J Green, Jonah R Chan, and Daniel S Lorrain Presented at Neuroscience 2019 The post The muscarinic M1 antagonist PIPE-359 demonstrates remyelination in vivo through visual evoked potential (VEP) and electron microscopy (EM) of mice with experimental autoimmune encephalitis (EAE) first appeared on Contineum Therapeutics.